3SBIO (01530.HK), a leading Chinese biopharmaceutical company, saw its stock price surge 5.19% in pre-market trading on Wednesday following the release of impressive full-year financial results and the announcement of a final dividend.
The company reported robust financial performance for the fiscal year, with revenue reaching RMB 9,108 million. 3SBIO demonstrated strong profitability, posting a basic earnings per share (EPS) of RMB 0.86 and maintaining an exceptionally high gross margin of 86%. The gross profit stood at RMB 7,828.4 million, while EBITDA and adjusted EBITDA came in at RMB 3,173.8 million and RMB 3,402.3 million, respectively.
Adding to investor enthusiasm, 3SBIO declared a final dividend of HKD25 cents per share, signaling confidence in the company's financial health and commitment to shareholder returns. This combination of strong financial results and a generous dividend payout appears to have fueled the significant pre-market rally, as investors respond positively to the company's performance and shareholder-friendly policies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。